[breadcrumb_custom]

Lyra Therapeutics Inc (NASDAQ: LYRA) Shares Are Down -7.06% Year To Date.

In the last trading session, 1.13 million Lyra Therapeutics Inc (NASDAQ:LYRA) shares changed hands as the company’s beta touched 0.17. With the company’s per share price at $4.87 changed hands at -$0.01 or -0.20% during last session, the market valuation stood at $255.97M. LYRA’s last price was a discount, traded about -18.07% off its 52-week high of $5.75. The share price had its 52-week low at $1.86, which suggests the last value was 61.81% up since then. When we look at Lyra Therapeutics Inc’s average trading volume, we note the 10-day average is 0.15 million shares, with the 3-month average coming to 4.86.

Lyra Therapeutics Inc (NASDAQ:LYRA) trade information

Instantly LYRA was in red as seen at the end of in last trading. With action -0.20%, the performance over the past five days has been red. The drop to weekly highs of 5.14 subtracted -0.20% to the stock’s daily price. The company’s shares are showing year-to-date downside of -7.06%, with the 5-day performance at -0.20% in the red. However, in the 30-day time frame, Lyra Therapeutics Inc (NASDAQ:LYRA) is -7.41% down. Looking at the short shares, we see there were 0.13 million shares sold at short interest cover period of 0.72 days.

#1 Small-Cap Uranium Stock for Ultra-Fast Gains in 2024

We've uncovered THE ONE small-cap uranium stock that has unearthed a near-surface, high-grade uranium discovery in the Saudi Arabia of Uranium — Canada's prolific Athabasca Basin. Best of all, this small-cap uranium stock is currently flying just below Wall Street's radar… giving you the early-entry opportunity around US$0.30 per share. But that won't last long. Drills are turning right now with results set to be released to the market very, very soon.

Learn all about it in this brand new FREE online report.
Sponsored

Lyra Therapeutics Inc (LYRA) estimates and forecasts

Data shows that the Lyra Therapeutics Inc share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 37.18% over the past 6 months, a 26.78% in annual growth rate that is considerably higher than the industry average of 11.60%.

Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of -40.24%. The 2024 estimates are for Lyra Therapeutics Inc earnings to increase by 28.51%, but the outlook for the next 5-year period is at -1.60% per year.

LYRA Dividends

Lyra Therapeutics Inc is expected to release its next quarterly earnings report in March.

Lyra Therapeutics Inc (NASDAQ:LYRA)’s Major holders

If we look at who the major shareholders are, we find that insiders hold 0.82% of Lyra Therapeutics Inc shares while 82.41% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 83.10%. There are 82.41% institutions holding the Lyra Therapeutics Inc stock share, with Perceptive Advisors Llc the top institutional holder. As of Jun 29, 2023, the company held 25.75% of the shares, roughly 12.76 million LYRA shares worth $52.43 million.

Armistice Capital, LLC holds the second largest percentage of outstanding shares, with 8.10% or 4.01 million shares worth $16.49 million as of Jun 29, 2023.

Among Mutual Funds, the top two as of Jun 29, 2023 were Vanguard Total Stock Market Index Fund and Vanguard Extended Market Index Fund. With 0.48 million shares estimated at $1.96 million under it, the former controlled 0.96% of total outstanding shares. On the other hand, Vanguard Extended Market Index Fund held about 0.61% of the shares, roughly 0.3 million shares worth around $1.24 million.

On Key

Related Posts